Biomarkers of vulnerable plaque: The missing link with ischemia

Biomarkers in Medicine

Volumn 4, Issue 3, 2010, Pages 375-383

  Muller, Olivier ^a   Barbato, Emanuele ^a   De Bruyne, Bernard ^a   Bartunek, Jozef ^a  

^a CARDIOVASCULAR CENTER   (Belgium)

Author keywords

Biomarker; Coronary artery disease; Ischemia; Vulnerable plaque

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CD40 LIGAND; CHOLINE; CREATINE KINASE; CREATINE KINASE MB; CYSTATIN C; FATTY ACID; GLUTATHIONE PEROXIDASE; INTERCELLULAR ADHESION MOLECULE 1; ISCHEMIA MODIFIED ALBUMIN; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN; MYELOPEROXIDASE; MYOGLOBIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A; PREGNANCY ASSOCIATED PROTEIN; SERUM AMYLOID A; TOLL LIKE RECEPTOR; TROPONIN; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE CORONARY SYNDROME; ANAMNESIS; ANGINA PECTORIS; ATHEROSCLEROTIC PLAQUE; CLINICAL DECISION MAKING; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DIFFERENTIAL DIAGNOSIS; ELECTROCARDIOGRAPHY; EMERGENCY WARD; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; MEDICAL ASSESSMENT; MEDICAL RESEARCH; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PREDICTIVE VALUE; REVIEW; SENSITIVITY AND SPECIFICITY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ALBUMINS; BIOLOGICAL MARKERS; CHOLINE; CORONARY ARTERY DISEASE; CYSTATIN C; FATTY ACIDS, NONESTERIFIED; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; TOLL-LIKE RECEPTORS; TROPONIN;

EID: 77953736190     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.59     Document Type: Review

References (67)

1. Lloyd-Jones D, Adams RJ, Brown TM et al.: Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 121(7), e46-e215 (2010).
2. Lloyd-Jones D, Adams R, Carnethon M et al.: Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119(3), e21-e181 (2009).
3. Knockaert DC, Buntinx F, Stoens N, Bruyninckx R, Delooz H: Chest pain in the emergency department: the broad spectrum of causes. Eur. J. Emerg. Med. 9(1), 25-30 (2002).
4. Karmen A, Wroblewski F, Ladue JS: Transaminase activity in human blood. J. Clin. Invest. 34(1), 126-131 (1955).
5. Anderson JL, Adams CD, Antman EM et al.: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 116(7), e148-e304 (2007).
6. Pope JH, Aufderheide TP, Ruthazer R et al.: Missed diagnoses of acute cardiac ischemia in the emergency department. N. Engl. J. Med. 342(16), 1163-1170 (2000).
7. Hansson GK, Libby P: The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 6(7), 508-519 (2006).
8. Ambrose JA, Tannenbaum MA, Alexopoulos D et al.: Angiographic progression of coronary artery disease and the development of myocardial infarction. J. Am. Coll. Cardiol. 12(1), 56-62 (1988).
9. Giroud D, Li JM, Urban P, Meier B, Rutishauer W: Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am. J. Cardiol. 69(8), 729-732 (1992).
10. Little WC, Constantinescu M, Applegate RJ et al.: Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 78(5 Pt 1), 1157-1166 (1988).
11. Burke AP, Kolodgie FD, Farb A et al.: Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 103(7), 934-940 (2001).
12. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM: Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 20(5), 1262-1275 (2000).
13. Falk E: Stable versus unstable atherosclerosis: clinical aspects. Am. Heart J. 138(5 Pt 2), S421-S425 (1999).
14. Davies MJ: The pathophysiology of acute coronary syndromes. Heart 83(3), 361-366 (2000).
15. Van Der Wal AC, Becker AE, Koch KT et al.: Clinically stable angina pectoris is not necessarily associated with histologically stable atherosclerotic plaques. Heart 76(4), 312-316 (1996).
16. Van Der Wal AC, Becker AE, Van Der Loos CM, Das PK: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89(1), 36-44 (1994).
17. Arbustini E, Dal Bello B, Morbini P et al.: Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart 82(3), 269-272 (1999).
18. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT: Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 90(2), 775-778 (1994).
19. Shaw LJ, Berman DS, Maron DJ et al.: Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 117(10), 1283-1291 (2008).
20. Tonino PA, De Bruyne B, Pijls NH et al.: Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N. Engl. J. Med. 360(3), 213-224 (2009).
21. Erne P, Schoenenberger AW, Zuber M et al.: Effects of anti-ischaemic drug therapy in silent myocardial ischaemia type I: the Swiss Interventional Study on Silent Ischaemia type I (SWISSI I): a randomized, controlled pilot study. Eur. Heart J. 28(17), 2110-2117 (2007).
22. Fujii K, Kobayashi Y, Mintz GS et al.: Intravascular ultrasound assessment of ulcerated ruptured plaques: a comparison of culprit and nonculprit lesions of patients with acute coronary syndromes and lesions in patients without acute coronary syndromes. Circulation 108(20), 2473-2478 (2003).
23. Hong MK, Mintz GS, Lee CW et al.: Comparison of coronary plaque rupture between stable angina and acute myocardial infarction: a three-vessel intravascular ultrasound study in 235 patients. Circulation 110(8), 928-933 (2004).
24. Manoharan G, Ntalianis A, Muller O et al.: Severity of coronary arterial stenoses responsible for acute coronary syndromes. Am. J. Cardiol. 103(9), 1183-1188 (2009).
25. + binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. Eur. J. Biochem. 268(1), 42-47 (2001).
26. Bar-Or D, Lau E, Winkler JV: A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia - a preliminary report. J. Emerg. Med. 19(4), 311-315 (2000).
27. Chan B, Dodsworth N, Woodrow J, Tucker A, Harris R: Site-specific N-terminal auto-degradation of human serum albumin. Eur. J. Biochem. 227(1-2), 524-528 (1995).
28. Roy D, Quiles J, Gaze DC, Collinson P, Kaski JC, Baxter GF: Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart 92(1), 113-114 (2006).
29. Bar-Or D, Winkler JV, Vanbenthuysen K, Harris L, Lau E, Hetzel FW: Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: a preliminary comparison to creatine kinase-MB, myoglobin, and troponin I. Am. Heart J. 141(6), 985-991 (2001).
30. Sinha MK, Gaze DC, Tippins JR, Collinson PO, Kaski JC: Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation 107(19), 2403-2405 (2003).
31. Quiles J, Roy D, Gaze D et al.: Relation of ischemia-modified albumin (IMA) levels following elective angioplasty for stable angina pectoris to duration of balloon-induced myocardial ischemia. Am. J. Cardiol. 92(3), 322-324 (2003).
32. Sinha MK, Vazquez JM, Calvino R, Gaze DC, Collinson PO, Kaski JC: Effects of balloon occlusion during percutaneous coronary intervention on circulating ischemia modified albumin and transmyocardial lactate extraction. Heart 92(12), 1852-1853 (2006).
33. Garrido IP, Roy D, Calvino R et al.: Comparison of ischemia-modified albumin levels in patients undergoing percutaneous coronary intervention for unstable angina pectoris with versus without coronary collaterals. Am. J. Cardiol. 93(1), 88-90 (2004).
34. Cho DK, Choi JO, Kim SH et al.: Ischemia-modified albumin is a highly sensitive serum marker of transient myocardial ischemia induced by coronary vasospasm. Coron. Artery Dis. 18(2), 83-87 (2007).
35. Peacock F, Morris DL, Anwaruddin S et al.: Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am. Heart J. 152(2), 253-262 (2006).
36. Sbarouni E, Georgiadou P, Kremastinos DT, Voudris V: Ischemia modified albumin: is this marker of ischemia ready for prime time use? Hellenic J. Cardiol. 49(4), 260-266 (2008).
37. Richieri GV, Ogata RT, Kleinfeld AM: A fluorescently labeled intestinal fatty acid binding protein. Interactions with fatty acids and its use in monitoring free fatty acids. J. Biol. Chem. 267(33), 23495-23501 (1992).
38. Azzazy HM, Pelsers MM, Christenson RH: Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications. Clin. Chem. 52(1), 19-29 (2006).
39. Apple FS, Wu AH, Mair J et al.: Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin. Chem. 51(5), 810-824 (2005).
40. Cantor WJ, Kim HH, Jolly S et al.: B-type natriuretic peptide and serum unbound free fatty acid levels after contemporary percutaneous coronary intervention. J. Invasive Cardiol. 20(4), 186-188 (2008).
41. Kleinfeld AM, Prothro D, Brown DL, Davis RC, Richieri GV, DeMaria A: Increases in serum unbound free fatty acid levels following coronary angioplasty. Am. J. Cardiol. 78(12), 1350-1354 (1996).
42. Danne O, Mockel M: Choline in acute coronary syndrome: an emerging biomarker with implications for the integrated assessment of plaque vulnerability. Expert Rev. Mol. Diagn. 10(2), 159-171.
43. Danne O, Lueders C, Storm C, Frei U, Mockel M: Whole-blood hypercholinemia and coronary instability and thrombosis. Clin. Chem. 51(7), 1315-1317 (2005).
44. Danne O, Mockel M, Lueders C et al.: Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. Am. J. Cardiol. 91(9), 1060-1067 (2003).
45. Mockel M, Danne O, Muller R et al.: Development of an optimized multimarker strategy for early risk assessment of patients with acute coronary syndromes. Clin. Chim. Acta. 393(2), 103-109 (2008).
46. LeLeiko RM, Vaccari CS, Sola S et al.: Usefulness of elevations in serum choline and free F2-isoprostane to predict 30-day cardiovascular outcomes in patients with acute coronary syndrome. Am. J. Cardiol. 104(5), 638-643 (2009).
47. Azzazy HM, Christenson RH: B-type natriuretic peptide: physiologic role and assay characteristics. Heart Fail. Rev. 8(4), 315-320 (2003).
48. De Lemos JA, McGuire DK, Drazner MH: B-type natriuretic peptide in cardiovascular disease. Lancet 362(9380), 316-322 (2003).
49. Marumoto K, Hamada M, Hiwada K: Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin. Sci. (Lond.) 88(5), 551-556 (1995).
50. Kyriakides ZS, Markianos M, Michalis L, Antoniadis A, Nikolaou NI, Kremastinos DT: Brain natriuretic peptide increases acutely and much more prominently than atrial natriuretic peptide during coronary angioplasty. Clin. Cardiol. 23(4), 285-288 (2000).
51. Mega JL, Morrow DA, De Lemos JA et al.: B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J. Am. Coll. Cardiol. 44(2), 335-339 (2004).
52. De Lemos JA, Morrow DA, Bentley JH et al.: The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N. Engl. J. Med. 345(14), 1014-1021 (2001).
53. Omland T, Sabatine MS, Jablonski KA et al.: Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE trial. J. Am. Coll. Cardiol. 50(3), 205-214 (2007).
54. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R: N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N. Engl. J. Med. 352(7), 666-675 (2005). (Pubitemid 40239214)
55. Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller NB, Whooley MA: N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 297(2), 169-176 (2007).
56. Tateishi J, Masutani M, Ohyanagi M, Iwasaki T: Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin. Cardiol. 23(10), 776-780 (2000).
57. Goetze JP, Christoffersen C, Perko M et al.: Increased cardiac BNP expression associated with myocardial ischemia. FASEB J. 17(9), 1105-1107 (2003).
58. Souza CJ, Gonzalez-Bulnes A, Campbell BK, McNeilly AS, Baird DT: Mechanisms of action of the principal prolific genes and their application to sheep production. Reprod. Fertil. Dev. 16(4), 395-401 (2004).
59. Deo R, Shlipak MG, Ix JH, Ali S, Schiller NB, Whooley MA: Association of cystatin C with ischemia in patients with coronary heart disease. Clin. Cardiol. 32(11), E18-E22 (2009).
60. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ: Expression of Toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105(10), 1158-1161 (2002).
61. Candore G, Aquino A, Balistreri CR et al.: Inflammation, longevity, and cardiovascular diseases: role of polymorphisms of TLR4. Ann. NY Acad. Sci. 1067, 282-287 (2006).
62. Norata GD, Garlaschelli K, Ongari M et al.: Effect of the Toll-like receptor 4 (TLR-4) variants on intima-media thickness and monocyte-derived macrophage response to LPS. J. Intern. Med. 258(1), 21-27 (2005).
63. Schoneveld AH, Oude Nijhuis MM, Van Middelaar B, Laman JD, De Kleijn DP, Pasterkamp G: Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development. Cardiovasc. Res. 66(1), 162-169 (2005).
64. Versteeg D, Hoefer IE, Schoneveld AH et al.: Monocyte Toll-like receptor 2 and 4 responses and expression following percutaneous coronary intervention: association with lesion stenosis and fractional flow reserve. Heart 94(6), 770-776 (2008).
65. Thygesen K, Alpert JS, White HD: Universal definition of myocardial infarction. J. Am. Coll. Cardiol. 50(22), 2173-2195 (2007). (Pubitemid 350123680)
66. Omland T, De Lemos JA, Sabatine MS et al.: A sensitive cardiac troponin T assay in stable coronary artery disease. N. Engl. J. Med. 361(26), 2538-2547 (2009).
67. Sabatine MS, Morrow DA, De Lemos JA, Jarolim P, Braunwald E: Detection of acute changes in circulating troponin In the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. Eur. Heart J. 30(2), 162-169 (2009).